Table 1 Baseline characteristics
Characteristic | Dapagliflozin group (n = 168) | Sitagliptin group (n = 163) | P-value |
|---|---|---|---|
Sex (male/female) n (%) | 104 (61.9)/64 (38.1) | 95 (58.3)/68 (41.7) | 0.57 |
Age (years) | 58.3 ± 12.4 | 57.9 ± 12.1 | 0.71 |
Body weight (kg) | 74.5 ± 13.4 | 74.9 ± 15.0 | 0.84 |
BMI (kg/m2) | 27.8 ± 4.0 | 27.9 ± 4.2 | 0.76 |
Systolic blood pressure (mmHg) | 134.6 ± 15.9 | 132.8 ± 15.7 | 0.28 |
Diastolic blood pressure (mmHg) | 80.5 ± 12.1 | 79.1 ± 11.0 | 0.25 |
Duration of diabetes (years) | 6.0 ± 6.4 | 5.6 ± 5.8 | 0.47 |
Fasting plasma glucose (mg/dL) | 151.7 ± 33.4 | 152.1 ± 30.7 | 0.92 |
HbA1c (NGSP %) | 7.8 ± 0.8 | 7.8 ± 0.8 | 0.90 |
HbA1c (mmol/mol) | 61.2 ± 8.4 | 61.2 ± 8.3 | 0.90 |
eGFR (mL/min/1.73 m2) | 79.0 ± 18.5 | 78.9 ± 16.9 | 0.97 |
Current smoking | 45 (26.8) | 47 (28.8) | 0.71 |
Microvascular complications | |||
 Diabetic retinopathy | 12 (7.6) | 10 (6.7) | 0.83 |
 Diabetic nephropathy | 15 (9.1) | 33 (20.5) | 0.005 |
 Diabetic neuropathy | 12 (7.5) | 7 (4.5) | 0.35 |
Macrovascular complications | |||
 Cerebrovascular disease | 2 (1.2) | 1 (0.6) | 1.00 |
 Coronary disease | 7 (4.2) | 4 (2.5) | 0.54 |
 Peripheral arterial disease | 1 (0.6) | 1 (0.6) | 1.00 |
Anti-diabetic drugs | 100 (59.5) | 95 (58.3) | 0.82 |
 Biguanides | 100 (59.5) | 95 (58.3) | 0.82 |
 Dose of biguanides (mg) | 561.9 ± 630.0 | 523.8 ± 577.3 | 0.57 |
Antihypertensive drugs | 71 (42.3) | 73 (44.8) | 0.66 |
 Diuretic drugs | 10 (6.0) | 20 (12.3) | 0.06 |
 Calcium channel blockers | 53 (31.5) | 49 (30.1) | 0.81 |
 ACE inhibitors | 1 (0.6) | 2 (1.2) | 0.62 |
 Angiotensin II receptor blockers | 52 (31.0) | 60 (36.8) | 0.30 |
 β-blockers | 5 (3.0) | 1 (0.6) | 0.21 |
 α-blockers | 1 (0.6) | 2 (1.2) | 0.62 |
Lipid-lowering agents | 72 (42.9) | 71 (43.6) | 0.91 |
 Statins | 60 (35.7) | 56 (34.4) | 0.82 |
 Fibrates | 12 (7.1) | 9 (5.5) | 0.65 |
 Ezetimibe | 5 (3.0) | 7 (4.3) | 0.57 |
 Eicosapentaenoic acid | 2 (1.2) | 5 (3.1) | 0.28 |